Which has higher earnings & valuation, SDGR or PHR?

Phreesia has higher revenue and earnings than Schrodinger. Schrodinger is trading at a lower price-to-earnings ratio than Phreesia, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Schrodinger $255.87M 7.87 -$103.26M -$0.74 N/A Phreesia $480.59M 1.39 $2.31M $0.17 63.46

Is SDGR or PHR more profitable?

Phreesia has a net margin of 2.06% compared to Schrodinger's net margin of -20.98%. Phreesia's return on equity of 5.22% beat Schrodinger's return on equity. Company Net Margins Return on Equity Return on Assets Schrodinger -20.98% -16.37% -8.19% Phreesia 2.06% 5.22% 3.02%

Does the media prefer SDGR or PHR?

In the previous week, Schrodinger had 1 more articles in the media than Phreesia. MarketBeat recorded 7 mentions for Schrodinger and 6 mentions for Phreesia. Schrodinger's average media sentiment score of 0.55 beat Phreesia's score of 0.37 indicating that Schrodinger is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Schrodinger 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Phreesia 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, CERT or PHR?

Phreesia has higher revenue and earnings than Certara. Certara is trading at a lower price-to-earnings ratio than Phreesia, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Certara $418.84M 3.33 -$1.60M -$0.45 N/A Phreesia $480.59M 1.39 $2.31M $0.17 63.46

Is CERT or PHR more profitable?

Phreesia has a net margin of 2.06% compared to Certara's net margin of -16.75%. Phreesia's return on equity of 5.22% beat Certara's return on equity. Company Net Margins Return on Equity Return on Assets Certara -16.75% 3.86% 2.65% Phreesia 2.06% 5.22% 3.02%

Does the media refer more to CERT or PHR?

In the previous week, Certara had 5 more articles in the media than Phreesia. MarketBeat recorded 11 mentions for Certara and 6 mentions for Phreesia. Certara's average media sentiment score of 0.69 beat Phreesia's score of 0.37 indicating that Certara is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Certara 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Phreesia 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, PHR or GDRX?

GoodRx has higher revenue and earnings than Phreesia. Phreesia is trading at a lower price-to-earnings ratio than GoodRx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Phreesia $480.59M 1.39 $2.31M $0.17 63.46 GoodRx $796.85M 1.47 $30.44M $0.04 85.75

Is PHR or GDRX more profitable?

GoodRx has a net margin of 2.07% compared to Phreesia's net margin of 2.06%. GoodRx's return on equity of 7.22% beat Phreesia's return on equity. Company Net Margins Return on Equity Return on Assets Phreesia 2.06% 5.22% 3.02% GoodRx 2.07% 7.22% 2.53%

Does the media favor PHR or GDRX?

In the previous week, Phreesia had 3 more articles in the media than GoodRx. MarketBeat recorded 6 mentions for Phreesia and 3 mentions for GoodRx. Phreesia's average media sentiment score of 0.37 beat GoodRx's score of 0.14 indicating that Phreesia is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phreesia 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral GoodRx 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor PHR or TDOC?

In the previous week, Teladoc Health had 5 more articles in the media than Phreesia. MarketBeat recorded 11 mentions for Teladoc Health and 6 mentions for Phreesia. Teladoc Health's average media sentiment score of 0.60 beat Phreesia's score of 0.37 indicating that Teladoc Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phreesia 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Teladoc Health 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, HSTM or PHR?

HealthStream has higher earnings, but lower revenue than Phreesia. HealthStream is trading at a lower price-to-earnings ratio than Phreesia, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio HealthStream $321.12M 3.01 $18.34M $0.72 46.01 Phreesia $480.59M 1.39 $2.31M $0.17 63.46

Does the media refer more to HSTM or PHR?

In the previous week, Phreesia had 1 more articles in the media than HealthStream. MarketBeat recorded 6 mentions for Phreesia and 5 mentions for HealthStream. Phreesia's average media sentiment score of 0.37 beat HealthStream's score of 0.13 indicating that Phreesia is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HealthStream 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Phreesia 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Phreesia (PHR) Competitors

$10.79 +0.13 (+1.21%)

Closing price 10/9/2026 03:59 PM Eastern

Extended Trading

$10.80 +0.01 (+0.10%)

As of 10/9/2026 07:30 PM Eastern

Compare

PHR vs. SDGR, CERT, GDRX, TDOC, and HSTM

Should you buy Phreesia stock or one of its competitors? Phreesia's main competitors and comparable companies include Schrodinger (SDGR), Certara (CERT), GoodRx (GDRX), Teladoc Health (TDOC), and HealthStream (HSTM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare technology" industry.

How does Phreesia compare to Schrodinger?

Schrodinger (NASDAQ:SDGR) and Phreesia (NYSE:PHR) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation, dividends and media sentiment.

Schrodinger presently has a consensus target price of $20.80, suggesting a potential downside of 23.75%. Phreesia has a consensus target price of $14.00, suggesting a potential upside of 29.76%. Given Phreesia's higher probable upside, analysts clearly believe Phreesia is more favorable than Schrodinger.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Schrodinger	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57
Phreesia	1 Sell rating(s)	10 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.37

Phreesia has a net margin of 2.06% compared to Schrodinger's net margin of -20.98%. Phreesia's return on equity of 5.22% beat Schrodinger's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Schrodinger	-20.98%	-16.37%	-8.19%
Phreesia	2.06%	5.22%	3.02%

Schrodinger has a beta of 1.62, suggesting that its stock price is 62% more volatile than the broader market. Comparatively, Phreesia has a beta of 0.84, suggesting that its stock price is 16% less volatile than the broader market.

79.1% of Schrodinger shares are held by institutional investors. Comparatively, 92.1% of Phreesia shares are held by institutional investors. 10.1% of Schrodinger shares are held by insiders. Comparatively, 5.2% of Phreesia shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Phreesia has higher revenue and earnings than Schrodinger. Schrodinger is trading at a lower price-to-earnings ratio than Phreesia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Schrodinger	$255.87M	7.87	-$103.26M	-$0.74	N/A
Phreesia	$480.59M	1.39	$2.31M	$0.17	63.46

In the previous week, Schrodinger had 1 more articles in the media than Phreesia. MarketBeat recorded 7 mentions for Schrodinger and 6 mentions for Phreesia. Schrodinger's average media sentiment score of 0.55 beat Phreesia's score of 0.37 indicating that Schrodinger is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Schrodinger	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Phreesia	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Phreesia beats Schrodinger on 10 of the 17 factors compared between the two stocks.

How does Phreesia compare to Certara?

Certara (NASDAQ:CERT) and Phreesia (NYSE:PHR) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, media sentiment, valuation and risk.

Phreesia has a net margin of 2.06% compared to Certara's net margin of -16.75%. Phreesia's return on equity of 5.22% beat Certara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Certara	-16.75%	3.86%	2.65%
Phreesia	2.06%	5.22%	3.02%

Certara currently has a consensus target price of $8.60, suggesting a potential downside of 5.81%. Phreesia has a consensus target price of $14.00, suggesting a potential upside of 29.76%. Given Phreesia's higher possible upside, analysts plainly believe Phreesia is more favorable than Certara.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Certara	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.42
Phreesia	1 Sell rating(s)	10 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.37

Phreesia has higher revenue and earnings than Certara. Certara is trading at a lower price-to-earnings ratio than Phreesia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Certara	$418.84M	3.33	-$1.60M	-$0.45	N/A
Phreesia	$480.59M	1.39	$2.31M	$0.17	63.46

In the previous week, Certara had 5 more articles in the media than Phreesia. MarketBeat recorded 11 mentions for Certara and 6 mentions for Phreesia. Certara's average media sentiment score of 0.69 beat Phreesia's score of 0.37 indicating that Certara is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Certara	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Phreesia	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Certara has a beta of 1.42, meaning that its share price is 42% more volatile than the broader market. Comparatively, Phreesia has a beta of 0.84, meaning that its share price is 16% less volatile than the broader market.

74.0% of Certara shares are owned by institutional investors. Comparatively, 92.1% of Phreesia shares are owned by institutional investors. 1.1% of Certara shares are owned by insiders. Comparatively, 5.2% of Phreesia shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Phreesia beats Certara on 11 of the 17 factors compared between the two stocks.

How does Phreesia compare to GoodRx?

Phreesia (NYSE:PHR) and GoodRx (NASDAQ:GDRX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership.

In the previous week, Phreesia had 3 more articles in the media than GoodRx. MarketBeat recorded 6 mentions for Phreesia and 3 mentions for GoodRx. Phreesia's average media sentiment score of 0.37 beat GoodRx's score of 0.14 indicating that Phreesia is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phreesia	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
GoodRx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

GoodRx has higher revenue and earnings than Phreesia. Phreesia is trading at a lower price-to-earnings ratio than GoodRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phreesia	$480.59M	1.39	$2.31M	$0.17	63.46
GoodRx	$796.85M	1.47	$30.44M	$0.04	85.75

92.1% of Phreesia shares are owned by institutional investors. Comparatively, 63.8% of GoodRx shares are owned by institutional investors. 5.2% of Phreesia shares are owned by company insiders. Comparatively, 5.9% of GoodRx shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Phreesia currently has a consensus target price of $14.00, indicating a potential upside of 29.76%. GoodRx has a consensus target price of $4.23, indicating a potential upside of 23.24%. Given Phreesia's stronger consensus rating and higher possible upside, equities research analysts clearly believe Phreesia is more favorable than GoodRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phreesia	1 Sell rating(s)	10 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.37
GoodRx	3 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.08

Phreesia has a beta of 0.84, suggesting that its share price is 16% less volatile than the broader market. Comparatively, GoodRx has a beta of 1.69, suggesting that its share price is 69% more volatile than the broader market.

GoodRx has a net margin of 2.07% compared to Phreesia's net margin of 2.06%. GoodRx's return on equity of 7.22% beat Phreesia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phreesia	2.06%	5.22%	3.02%
GoodRx	2.07%	7.22%	2.53%

Summary

Phreesia and GoodRx tied by winning 8 of the 16 factors compared between the two stocks.

How does Phreesia compare to Teladoc Health?

Phreesia (NYSE:PHR) and Teladoc Health (NYSE:TDOC) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, media sentiment, institutional ownership and valuation.

Phreesia presently has a consensus price target of $14.00, indicating a potential upside of 29.76%. Teladoc Health has a consensus price target of $7.54, indicating a potential upside of 30.35%. Given Teladoc Health's higher probable upside, analysts plainly believe Teladoc Health is more favorable than Phreesia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phreesia	1 Sell rating(s)	10 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.37
Teladoc Health	1 Sell rating(s)	10 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.25

Phreesia has higher earnings, but lower revenue than Teladoc Health. Teladoc Health is trading at a lower price-to-earnings ratio than Phreesia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phreesia	$480.59M	1.39	$2.31M	$0.17	63.46
Teladoc Health	$2.53B	0.42	-$200.32M	-$0.99	N/A

Phreesia has a net margin of 2.06% compared to Teladoc Health's net margin of -7.13%. Phreesia's return on equity of 5.22% beat Teladoc Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phreesia	2.06%	5.22%	3.02%
Teladoc Health	-7.13%	-12.15%	-5.83%

Phreesia has a beta of 0.84, suggesting that its stock price is 16% less volatile than the broader market. Comparatively, Teladoc Health has a beta of 2.14, suggesting that its stock price is 114% more volatile than the broader market.

92.1% of Phreesia shares are owned by institutional investors. Comparatively, 76.8% of Teladoc Health shares are owned by institutional investors. 5.2% of Phreesia shares are owned by company insiders. Comparatively, 0.7% of Teladoc Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Teladoc Health had 5 more articles in the media than Phreesia. MarketBeat recorded 11 mentions for Teladoc Health and 6 mentions for Phreesia. Teladoc Health's average media sentiment score of 0.60 beat Phreesia's score of 0.37 indicating that Teladoc Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phreesia	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Teladoc Health	3 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Phreesia beats Teladoc Health on 11 of the 16 factors compared between the two stocks.

How does Phreesia compare to HealthStream?

HealthStream (NASDAQ:HSTM) and Phreesia (NYSE:PHR) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, risk, institutional ownership, valuation, dividends, earnings and analyst recommendations.

HealthStream has a net margin of 6.60% compared to Phreesia's net margin of 2.06%. HealthStream's return on equity of 6.81% beat Phreesia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HealthStream	6.60%	6.81%	4.64%
Phreesia	2.06%	5.22%	3.02%

HealthStream has a beta of 0.42, suggesting that its stock price is 58% less volatile than the broader market. Comparatively, Phreesia has a beta of 0.84, suggesting that its stock price is 16% less volatile than the broader market.

HealthStream has higher earnings, but lower revenue than Phreesia. HealthStream is trading at a lower price-to-earnings ratio than Phreesia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HealthStream	$321.12M	3.01	$18.34M	$0.72	46.01
Phreesia	$480.59M	1.39	$2.31M	$0.17	63.46

69.6% of HealthStream shares are held by institutional investors. Comparatively, 92.1% of Phreesia shares are held by institutional investors. 20.4% of HealthStream shares are held by insiders. Comparatively, 5.2% of Phreesia shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

HealthStream currently has a consensus price target of $27.00, suggesting a potential downside of 18.50%. Phreesia has a consensus price target of $14.00, suggesting a potential upside of 29.76%. Given Phreesia's stronger consensus rating and higher probable upside, analysts plainly believe Phreesia is more favorable than HealthStream.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HealthStream	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33
Phreesia	1 Sell rating(s)	10 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.37

In the previous week, Phreesia had 1 more articles in the media than HealthStream. MarketBeat recorded 6 mentions for Phreesia and 5 mentions for HealthStream. Phreesia's average media sentiment score of 0.37 beat HealthStream's score of 0.13 indicating that Phreesia is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HealthStream	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Phreesia	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Phreesia beats HealthStream on 9 of the 16 factors compared between the two stocks.

Get Phreesia News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PHR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PHR vs. The Competition

Export

Metric	Phreesia	Healthcare Technology Industry	Healthcare Sector	NYSE Exchange
Market Cap	$661.68M	$1.81B	$7.16B	$22.94B
Dividend Yield	N/A	3.96%	2.53%	3.72%
P/E Ratio	63.47	21.78	274.15	28.60
Price / Sales	1.39	95.31	635.98	15.12
Price / Cash	14.28	31.98	76.38	37.72
Price / Book	1.93	6.25	11.21	4.72
Net Income	$2.31M	-$19.09M	$3.50B	$1.07B
7 Day Performance	6.98%	-0.57%	-0.90%	0.35%
1 Month Performance	6.15%	1.40%	-4.44%	-2.93%
1 Year Performance	-51.64%	-19.77%	6.96%	9.26%

Phreesia Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PHR Phreesia	4.1255 of 5 stars	$10.79 +1.2%	$14.00 +29.8%	-54.8%	$661.68M	$480.59M	63.47	1,789	News Coverage Analyst Upgrade
SDGR Schrodinger	2.2616 of 5 stars	$29.50 +2.3%	$20.80 -29.5%	+32.1%	$2.13B	$255.87M	N/A	850	News Coverage
CERT Certara	1.917 of 5 stars	$9.13 +0.2%	$8.28 -9.3%	-29.4%	$1.39B	$418.84M	N/A	1,576	News Coverage Analyst Forecast Options Volume Gap Up
GDRX GoodRx	4.1267 of 5 stars	$3.31 -1.2%	$4.23 +27.7%	-26.1%	$1.15B	$796.85M	82.77	697
TDOC Teladoc Health	3.2528 of 5 stars	$5.90 -3.2%	$7.54 +27.8%	-34.6%	$1.11B	$2.53B	N/A	5,600

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:PHR) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Phreesia (PHR) Competitors

PHR vs. SDGR, CERT, GDRX, TDOC, and HSTM

How does Phreesia compare to Schrodinger?

Summary

How does Phreesia compare to Certara?

Summary

How does Phreesia compare to GoodRx?

Summary

How does Phreesia compare to Teladoc Health?

Summary

How does Phreesia compare to HealthStream?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHR vs. The Competition

Phreesia Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Phreesia (PHR) Competitors

PHR vs. SDGR, CERT, GDRX, TDOC, and HSTM

How does Phreesia compare to Schrodinger?

Do analysts recommend SDGR or PHR?

Is SDGR or PHR more profitable?

Which has more volatility & risk, SDGR or PHR?

Do insiders & institutionals hold more shares of SDGR or PHR?

Which has higher earnings & valuation, SDGR or PHR?

Does the media prefer SDGR or PHR?

Summary

How does Phreesia compare to Certara?

Is CERT or PHR more profitable?

Do analysts rate CERT or PHR?

Which has preferable earnings & valuation, CERT or PHR?

Does the media refer more to CERT or PHR?

Which has more risk and volatility, CERT or PHR?

Do insiders & institutionals hold more shares of CERT or PHR?

Summary

How does Phreesia compare to GoodRx?

Does the media favor PHR or GDRX?

Which has preferable valuation and earnings, PHR or GDRX?

Do insiders and institutionals believe in PHR or GDRX?

Do analysts rate PHR or GDRX?

Which has more risk & volatility, PHR or GDRX?

Is PHR or GDRX more profitable?

Summary

How does Phreesia compare to Teladoc Health?

Do analysts rate PHR or TDOC?

Which has stronger earnings & valuation, PHR or TDOC?

Is PHR or TDOC more profitable?

Which has more risk and volatility, PHR or TDOC?

Do insiders & institutionals believe in PHR or TDOC?

Does the media favor PHR or TDOC?

Summary

How does Phreesia compare to HealthStream?

Is HSTM or PHR more profitable?

Which has more risk & volatility, HSTM or PHR?

Which has higher earnings & valuation, HSTM or PHR?

Do insiders and institutionals have more ownership in HSTM or PHR?

Do analysts rate HSTM or PHR?

Does the media refer more to HSTM or PHR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHR vs. The Competition

Phreesia Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools